William Martin, MD
Family Medicine · North Conway, NHNPI 1215115639
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 326 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 35.0% of the total. Among family medicine clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 326 payments — averaging $14.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- GSK$423
- Novo Nordisk$401
- Johnson & Johnson$393
- Pfizer$331
- Sunovion Pharmaceuticals Inc.$238
- plus $1K from 23 others
What the payments were for
- Food & beverage$4,836100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 115 | $1,695 |
| GSK | 32 | $423 |
| Novo Nordisk | 27 | $401 |
| Johnson & Johnson | 25 | $393 |
| Pfizer | 23 | $331 |
| Sunovion Pharmaceuticals Inc. | 15 | $238 |
| Merck | 20 | $220 |
| Ironwood Pharmaceuticals, Inc | 10 | $160 |
| Amgen | 10 | $150 |
| Novartis | 8 | $142 |
| AstraZeneca | 6 | $95 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $70 |
| Nestle Healthcare Nutrition Inc. | 4 | $62 |
| Corcept Therapeutics | 3 | $59 |
| Supernus Pharmaceuticals, Inc. | 1 | $57 |
| Dexcom, Inc. | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $49 |
| Xeris Pharmaceuticals, Inc. | 2 | $45 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Vapotherm Inc | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $22 |
| Optinose US, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Abbott | 1 | $13 |
| Kaleo, Inc. | 1 | $11 |
How this compares
$4,836 in reported general payments places this provider in the 95th percentile of 397 family medicine providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 262 | $309,835 |
| MounjaroTirzepatide | 243 | $288,828 |
| EliquisApixaban | 182 | $222,671 |
| RybelsusSemaglutide | 54 | $88,605 |
| TrulicityDulaglutide | 68 | $85,649 |
| OzempicSemaglutide | 53 | $83,476 |
| Xeljanz XrTofacitinib Citrate | 12 | $66,435 |
| JanuviaSitagliptin Phosphate | 43 | $53,537 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $52,164 |
| LinzessLinaclotide | 52 | $52,110 |
| GlyxambiEmpagliflozin/Linagliptin | 32 | $49,631 |
| TradjentaLinagliptin | 40 | $41,483 |
| Tresiba Flextouch U-100Insulin Degludec | 44 | $40,861 |
| ProliaDenosumab | 21 | $35,550 |
| XareltoRivaroxaban | 26 | $33,318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta, Synjardy Xr | $14 | $424,974348 claims |
| Lilly USA, LLCMounjaro, Trulicity | $15 | $374,477311 claims |
| PfizerEliquis, Lipitor, Premarin | $331 | $249,889214 claims |
| Novo NordiskRybelsus, Ozempic | $401 | $172,081107 claims |
| MerckJanuvia, Janumet Xr | $220 | $77,37561 claims |
| AbbVieLinzess, Ubrelvy, Synthroid | $1,695 | $75,444142 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $423 | $69,31693 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $95 | $52,66086 claims |
| AmgenProlia | $150 | $35,55021 claims |
| Johnson & JohnsonXarelto | $393 | $33,31826 claims |
| NovartisEntresto | $142 | $26,14828 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $49 | $10,64811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 397 family medicine providers in New Hampshire.
Other family medicine in North Conway
- Brian SponsellerNorth Conway$15K
- Sohaib SiddiquiNorth Conway$2K
- Mark BallentynePortsmouth$135K
- M LauterPortsmouth$21K
- Cecilia Vicuna KeadyCharlestown$13K
- Keenan Al-HojerryPortsmouth$11K
- Peter LoeserConcord$10K
- Robyn StewartDerry$8K
- Robert KellyExeter$8K
- Dennis BadmanSanbornville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.